

# Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura

Information for the public

Published: 16 December 2020

[www.nice.org.uk](http://www.nice.org.uk)

Caplacizumab (Cablivi) with plasma exchange and immunosuppression is available on the NHS as a possible treatment for an acute episode of acquired thrombotic thrombocytopenic purpura in:

- adults and
- young people aged 12 years and over who weigh at least 40 kg.

Treatment should be started and supervised by doctors experienced in managing thrombotic microangiopathies.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

These organisations can give you advice and support:

- [AOFAC Foundation](#), 07404 553 898
- [TTPNetwork](#), [info@ttpnetwork.org.uk](mailto:info@ttpnetwork.org.uk)
- [Genetic Alliance UK](#), 0300 124 0441

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3949-7